Recent studies suggest that the main driving force behind the therapeutic activity observed
in mesenchymal stem cells (MSCs) are the paracrine factors secreted by these cells. These …

Mesenchymal stem cells (MSCs) may be derived from adult bone marrow, fat, and several
fetal tissues. In vitro, MSCs can be expanded and have the capacity to differentiate into …

We recently demonstrated that marrow stromal cells (MSCs) augment collateral remodeling
through release of several cytokines such as VEGF and bFGF rather than via cell …

Background—Systemic delivery of bone marrow–derived mesenchymal stem cells (BM-
MSCs) is an attractive approach for myocardial repair. We aimed to test this strategy in a rat …

Background—Bone marrow cell therapy is reported to contribute to collateral formation
through cell incorporation into new or remodeling vessels. However, the possible role of a …

Background—Experimental data suggest that bone marrow–derived cells may contribute to
the healing of myocardial infarction (MI). For this reason, we analyzed 10 patients who were …

We previously reported that intramyocardial injection of bone marrow‐derived mesenchymal
stem cells overexpressing Akt (Akt‐MSCs) inhibits ventricular remodeling and restores …

BACKGROUND: There are several reports that engrafted mesenchymal stem cells (MSCs)
stimulate angiogenesis in the ischemic heart, but the mechanism remains controversial. We …

Neovascularization induced by vascular endothelial growth factor (VEGF) represents an
appealing approach for treating ischemic heart disease. However, VEGF therapy has been …

Background—Delivery and tracking of endomyocardial stem cells are limited by the inability
to image transplanted cells noninvasively in the beating heart. We hypothesized that …